Related references
Note: Only part of the references are listed.250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
Sreeram V. Ramagopalan et al.
LANCET NEUROLOGY (2010)
The mechanism of action of glatiramer acetate treatment in multiple sclerosis
Michael K. Racke et al.
NEUROLOGY (2010)
Interferon-β mechanisms of action in multiple sclerosis
Suhayl Dhib-Jalbut et al.
NEUROLOGY (2010)
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
Francesco Patti
Patient Preference and Adherence (2010)
Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis
Sabine Cepok et al.
ARCHIVES OF NEUROLOGY (2009)
IFN-β1a Inhibits the Secretion of Th17-Polarizing Cytokines in Human Dendritic Cells via TLR7 Up-Regulation
Xin Zhang et al.
JOURNAL OF IMMUNOLOGY (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study
C. Weber-Schoendorfer et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
D. Cadavid et al.
NEUROLOGY (2009)
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis
Danielle Burger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses
Sonali Joshi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Interferon-β increases BAFF levels in multiple sclerosis:: implications for B cell autoimmunity
M. Krumbholz et al.
BRAIN (2008)
Long-term study of brain 1H-MRS study in multiple sclerosis:: Effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term 1H-MRS monitoring in multiple sclerosis
Omar Khan et al.
JOURNAL OF NEUROIMAGING (2008)
Inhibition of multiple sclerosis-associated retrovirus as biomarker of interferon therapy
Giuseppe Mameli et al.
JOURNAL OF NEUROVIROLOGY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS)
Toshimasa Aranami et al.
ALLERGOLOGY INTERNATIONAL (2008)
Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients
Marta Garcia-Montojo et al.
JOURNAL OF NEUROVIROLOGY (2007)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos et al.
LANCET (2007)
Glatiramer acetate: Mechanisms of action in multiple sclerosis
Wiebke Schrempf et al.
AUTOIMMUNITY REVIEWS (2007)
Interferon-beta - Mechanism of action and dosing issues
Clyde E. Markowitz
NEUROLOGY (2007)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
D. S. Goodin et al.
NEUROLOGY (2007)
Effects of interferon beta-1a and-1b over time: 6-year results of an observational head-to-head study
F Patti et al.
ACTA NEUROLOGICA SCANDINAVICA (2006)
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
CC Ford et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis:: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis
PS Sorensen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
The reproductive effects of beta interferon therapy in pregnancy - A longitudinal cohort
R Boskovic et al.
NEUROLOGY (2005)
Interferon-β-1a induces increases in vascular cell adhesion molecule:: implications for its mode of action in multiple sclerosis
J Graber et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study
MS Freedman et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Effect of interferon β-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients -: One year follow-up results
R Karabudak et al.
JOURNAL OF NEUROLOGY (2004)
In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis
M Schmied et al.
CLINICAL IMMUNOLOGY (2003)
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
L Durelli et al.
LANCET (2002)
Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
DS Goodin et al.
NEUROLOGY (2002)
Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis
MK Sharief et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b
S Narayanan et al.
JOURNAL OF NEUROLOGY (2001)
Mechanisms of action of glatiramer acetate in multiple sclerosis
O Neuhaus et al.
NEUROLOGY (2001)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1b
C Iarlori et al.
JOURNAL OF NEUROIMMUNOLOGY (2000)
Share Paper
